Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.
about
Exploring stakeholder perceptions of facilitators and barriers to using needle exchange programs in Yunnan Province, ChinaLong-term effects of methadone maintenance treatment with different psychosocial intervention modelsPaying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trialCharacterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, TajikistanHIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.HIV/AIDS and drug use in China--interactions, impacts, and issues.The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial."We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine.Linking HIV-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS Program.Opportunities to diagnose, treat, and prevent HIV in the criminal justice system.HIV risks and seroprevalence among Mexican American injection drug users in CaliforniaIntegrating buprenorphine treatment into office-based practice: a qualitative studyAddressing injecting drug use in Asia and Eastern Europe.The HIV epidemic in Eastern Europe and Central Asia.Prevention of HIV infection among injection drug users in resource-limited settings.Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.Methadone tolerance testing in drug misusers.Drug treatment as HIV prevention: a research updateDrug treatment as HIV prevention: expanding treatment options.Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058Achieving a high coverage--the challenge of controlling HIV spread in heroin usersProgress in HIV reduction and prevention among injection and noninjection drug users.Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trialThe effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.Managing la malilla: Exploring drug treatment experiences among injection drug users in Tijuana, Mexico, and their implications for drug law reformPharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence.Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusersFacilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial.Opioid dependence: rationale for and efficacy of existing and new treatments.Opioid maintenance: a comparative review of pharmacological strategies.Internalized HIV and Drug Stigmas: Interacting Forces Threatening Health Status and Health Service Utilization Among People with HIV Who Inject Drugs in St. Petersburg, RussiaMethadone maintenance treatment and mortality in HIV-positive people who inject opioids in ChinaHuman resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services.Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania.Nurse practitioner and physician assistant interest in prescribing buprenorphine.Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions.Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States.
P2860
Q28539429-78147E7E-0864-4614-9DDB-D4BC4836D869Q28539468-65C48217-6BD7-415B-A78D-6DAC87AF47CBQ33696533-0109C62D-3111-4898-82A1-925B7341F587Q33700165-3DA3D880-155A-437C-BB01-C0DC79A10806Q33807622-1EB7828D-430D-4B4A-B9B3-B37246B1BDD3Q34098066-3CADA5A2-D33F-4FB2-97D6-131CB73D842AQ34119447-1B7ED2E9-A3A9-4822-9F58-9857A5AA2322Q34135584-DEEF05C9-62FE-4BAB-BAED-0ABC4480DD8CQ34188736-F60EF196-6CFD-4191-B3BD-B13C5F14A5A7Q34420161-C841F0A9-53AB-445C-B4E5-C357901A1E81Q34472876-3D279D4C-B1BB-46F6-B40E-EDE7F2C8FCDAQ34500961-C731A4BE-0E7C-4E12-A729-D425D128ADDBQ34602077-684D5104-C23B-4AC1-87E0-50E33F2A56FFQ34648865-1A972D6F-F5C5-4855-B9D9-2D8328477367Q34660521-D4584BE5-97B0-4284-B8E5-5FCC79F560BBQ35043964-CA4705D7-FD88-4128-9B2F-449E9DE5EC8FQ35061983-E7EFFB35-E704-43A0-BC8E-AB16CA1354BFQ35148161-F9987D10-F83C-4088-854E-EC1C0806A38FQ35163392-38C11E04-0D93-4305-8089-FCF1119802C6Q35163396-43EAF0CE-4889-4ED1-AC1A-E1C2D10025CCQ35244943-08CB1E91-E10E-47C8-AB2E-99B91579E676Q35652957-BA951865-EF5B-4105-A455-16C411DF7779Q35816921-543E4EFE-0067-4677-B9D7-7ED60832B6A6Q35817533-B8D6EE2D-C96A-4E61-BD0D-C5FBC6E6A8E9Q35878056-37496E05-A3EC-428E-9360-A1A659EE3905Q35962516-CB50877D-CFFE-4A28-889B-83CB0D461F5BQ36239275-A3199461-9AB5-414E-B150-0D81BDB41ABEQ36248583-E68B4D05-5930-48CA-9BE0-E0401F478615Q36372149-188BAA3B-D39E-4A17-9D15-84B4C87386C7Q36376967-9F4D89B1-0C4E-43A0-B528-A88B4C6E6A60Q36655042-6D861B2A-E589-4579-BFA6-D16A910A8F01Q36681297-9C6B9D59-1588-414C-9B4B-3065205B863FQ36692131-C5945059-4E54-4E6F-AA89-0DA2E01839FEQ36706986-059E6BE3-52C7-49BA-9710-E293E1BFDD32Q36706991-26A4EBEE-57B3-4F0A-B5CF-C1DED16C4F25Q36745453-2C17B08F-FB7C-4B1E-8800-9140B4237E4BQ36792005-3A7A0E42-C40F-4C5B-A549-B6546C935D29Q36793941-22FF2510-F0BD-4676-8D3C-CD767A57EAEFQ36952590-EEE16AA8-1A32-4D56-A475-55489E431EE2Q36963114-6ABCFA3F-D338-4142-A0CB-6CAC2D1BF2F9
P2860
Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Decreasing international HIV t ...... pies for injection drug users.
@ast
Decreasing international HIV t ...... pies for injection drug users.
@en
Decreasing international HIV t ...... pies for injection drug users.
@nl
type
label
Decreasing international HIV t ...... pies for injection drug users.
@ast
Decreasing international HIV t ...... pies for injection drug users.
@en
Decreasing international HIV t ...... pies for injection drug users.
@nl
prefLabel
Decreasing international HIV t ...... pies for injection drug users.
@ast
Decreasing international HIV t ...... pies for injection drug users.
@en
Decreasing international HIV t ...... pies for injection drug users.
@nl
P2093
P2860
P921
P1433
P1476
Decreasing international HIV t ...... pies for injection drug users.
@en
P2093
David S Metzger
Lynn E Sullivan
Paul J Fudala
P2860
P304
P356
10.1111/J.1360-0443.2004.00963.X
P407
P577
2005-02-01T00:00:00Z